There is an enormous interest in performing high-quality, coordinated clinical trials not currently available in the hepatology community. The Liver Clinical Trials Network (LCTN) answers this need by connecting sponsors and investigators to a comprehensive system of scientists, academic thought leaders, and participating physicians. The New York Presbyterian Healthcare System, which includes the Columbia Presbyterian and the New York Weill Cornell Centers of New York Presbyterian Hospital as well as a complex of community hospitals, clinics and private practices, offers LCTN, one of the largest coordinated networks of liver patients in the country.
Dr. Robert S. Brown, Jr. and Dr. Ira Jacobson, the Co-Directors of the LCTN, and their medical advisory team supervise investigative studies on liver disease including transplantation. Special emphasis is placed on the new epidemic of hepatitis C, bio-artificial liver support, hepatitis B, cirrhosis, novel immunosuppressive strategies and prevention of recurrent viral diseases following transplantation. Additionally, the LCTN, in conjunction with the New York Psychiatric Institute, will create a program to study and treat alcoholism, a major cause of liver disease, and a barrier to liver transplantation.
The LCTN has a unique partnership with the Center for Liver Disease and Transplantation at New York Presbyterian Hospital. Our network links the hepatologists at the Center with other hospitals to optimize the care patients receive close to home, without limiting access to innovative treatment. But the transplant program is only one part of our overall effort; the LCTN makes available state-of-the-art medical and surgical therapy for all liver diseases.
AREAS OF THERAPEUTIC FOCUS LCTN
Alcoholic liver disease
Bio-artificial liver support
Cirrhosis and portal hypertension
Liver cell transplantation for
Medical therapy of cholestatic
Research in clinical immunosuppression for transplantation and auto-immune diseases
Technical research to increase the donor supply (partial liver transplants)
Therapy for viral hepatitis (B,C) prior to and following transplantation
The LCTN also tests therapies for less common diseases such as pediatric liver disease and liver cancer. Only a broad patient base and far-reaching network such as ours can effectively create investigative studies and treatment for these illnesses. But whether it is a rare disorder or the most common form of hepatitis, the LCTN is prepared to deliver meticulous, well-researched data that will help to improve the lives of our patients.
Robert S. Brown, Jr., M.D., M.P.H. (at left) Co-Director of LCTN, Associate Professor of Clinical Medicine, Pediatrics and Health Policy and Management, Columbia University College of Physicians and Surgeons, Medical Director of the Center of Liver Disease and Transplantation, and Chief of Clinical Hepatology at the Columbia Presbyterian Center. Dr. Browns research focuses on epidemiology and treatment of viral diseases prior to and following liver transplantation and conducting outcomes research in liver disease and transplantation. He has received numerous grants from the NIH, industry and professional societies. Currently, he is on the executive committee of a multi-center NIH trial for the prevention of recurrent hepatitis B following liver transplantation and has served on the Data Safety Monitoring Board for multi-center trials of immunosuppressive regimens.
Ira Jacobson, M.D. (at right) Co-Director of LCTN, Associate Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at the Weill Medical College of Cornell University and head of the gastroenterology service at the New York Weill Cornell Center of the New York Presbyterian Hospital. He is the past President of the New York Gastroenterological Association and the New York Society for Gastrointestinal Endoscopy and is the Manhattan Governor of the American College of Gastroenterology. Dr. Jacobson has been involved in numerous clinical trials assessing antiviral therapy for hepatitis B and C, including the original multi-center studies of interferon for each of these diseases. His recent work has focused on national multi-center studies as well as investigator-initiated studies on combination therapy with ribavirin and interferon for hepatitis C, along with studies on lamivudine for chronic hepatitis B. Dr. Jacobsons other interests include diseases of the biliary tract, and he has edited two books on endoscopy of the bile ducts and pancreas. He has an active practice concentrating on liver and biliary tract diseases and lectures extensively on hepatitis in the New York metropolitan area and nationally.
Jean C. Emond, M.D. Professor of Surgery, Columbia University College of Physicians and Surgeons, Surgical Director of the Center for Liver Disease and Transplantation at New York Presbyterian Hospital, is highly regarded in the field of liver transplantation for his innovative expertise in living related donor transplantation. Dr. Emond was a key member of the team that performed the first partial liver transplant in North America.
Stephen P. Esposito, M.D., P.C. Assistant Professor, Weill Medical College of Cornell University and the Director of Liver Disease and Clinical Research, New York Hospital Medical Center of Queens. Dr. Esposito is also the Director of the Hepatobiliary Clinic, New York Hospital Medical Center of Queens and Medical Advisor for HELLP, a non-profit liver support group. He is currently the Co-Investigator in numerous trials for the treatment of hepatitis C.
Jay H. Lefkowitch, M.D. Professor of Clinical Pathology, Columbia University College of Physicians and Surgeons with a specialty in the pathology of liver disease. Dr. Lefkowitch is a leading authority on liver pathology and has been a co-author of four pathology textbooks. Currently, he is the co-author of the sixth edition of Liver Biopsy Interpretation.
Howard J. Worman, M.D. Associate Professor of Medicine and of Anatomy and Cell Biology, Columbia University College of Physicians and Surgeons, is a hepatologist and research scientist specializing in liver cell biology. Dr. Worman holds several research grants and has published extensively in the area of liver disease.